Month: August 2020

55687-34-8, 6-Bromoquinoxalin-2(1H)-one is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Compound 39 (600 mg, 2.66 mmol) was added to cold phosphorous oxychloride (4 mL) in portions wise to give a slurry. To the resulting slurry was added drop wise N,N- dimethylaniline (0.4 ml, 2.93 mmol) below 15C. The brick red mixture was refluxed for 15 min, and the resulting dark brown clear solution was then cooled to ambient temperature. It was added to ice cold water (40 mL) , and the mixture was basified slowly with 40% aq. NaOH to pH 8. The solid was collected by filtration, washed with water (2×10 mL) and dried to give the title compound 40 (70%) .

55687-34-8 6-Bromoquinoxalin-2(1H)-one 12686394, aquinoxaline compound, is more and more widely used in various.

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; BANDYOPADHYAY, Anish; SARANGTHEM, Robindro; BARAWKAR, Dinesh; BONAGIRI, Rajesh; KHOSE, Goraksha; SHINDE, Shailesh; (226 pag.)WO2016/199943; (2016); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (149 mg, 0.777 mmol) and 1-hydroxybenzotriazole monohydrate (105 mg, 0.777 mmol), were added to a methylene chloride solution (5.0 ml) of the resulting compound (180 mg, 0.518 mmol) and 3-hydroxyquinoxaline-2-carboxylic acid (148 mg, 0.777 mmol), at room temperature, under nitrogen stream, followed by further addition of triethylamine (0.289 ml, 2.07 mmol), and stirring was carried out at room temperature overnight. The reaction solution was poured into a 2N aqueous hydrochloric acid solution, followed by extraction with ethyl acetate and sequential washing with water, a saturated aqueous sodium hydrogencarbonate solution, water and saline, and then the resulting organic layer was dried over anhydrous sodium sulfate. After the organic layer was concentrated and the resulting residue was purified by a medium-pressure preparative liquid chromatograph (manufactured by Biotage, Inc., 25+M), the residue resulting from concentration was suspended in a mixed solvent of methylene chloride-diethyl ether, and the solid substance was collected by filtration to afford the desired title compound (113 mg, yield 45%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.86 (1H, s), 10.19 (1H, s), 7.97 (1H, t, J=7.0 Hz), 7.61 (1H, s), 7.53 (1H, s), 7.36 (1H, s), 7.26 (2H, t, J=7.0 Hz), 6.86 (2H, t, J=7.0 Hz), 5.09-5.07 (1H, m), 4.57-4.55 (1H, m), 4.01-3.68 (4H, m), 2.21-2.02 (5H, m), 1.14-1.11 (6H, m). IR (KBr) cm-1: 2960, 1690, 1640, 1490, 1240, 1150. MS (FAB, m/z): 483 (M+H)+. HRMS (ESI, m/z): 483.1797 (Calcd for C25H28ClN4O4: 483.1799).

As the paragraph descriping shows that 1204-75-7 is playing an increasingly important role.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (115 mg, 0.600 mmol) and 1-hydroxybenzotriazole monohydrate (91.0 mg, 0.600 mmol) were added to a methylene chloride solution (5.0 ml) of the resulting compound (160 mg, 0.500 mmol) and 3-hydroxyquinoxaline-2-carboxylic acid (98.0 mg, 0.500 mmol), at room temperature, under nitrogen stream, followed by further addition of N-methylmorpholine (0.270 ml, 2.50 mmol), and stirring was carried out at room temperature overnight. The reaction solution was diluted with methylene chloride, followed by sequential washing with a saturated aqueous sodium hydrogencarbonate solution, a saturated aqueous ammonium chloride solution, water and saline, and then the resulting organic layer was dried over anhydrous sodium sulfate. After the organic layer was concentrated and the resulting residue was purified by a medium-pressure preparative liquid chromatograph (manufactured by Biotage, Inc., 25+M), the residue resulting from concentration was suspended in a mixed solvent of methylene chloride-ethyl acetate, and the solid substance was collected by filtration to afford the desired title compound (130 mg, yield 57%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.86 (1H, brs), 9.71 (1H, brs), 7.88 (1H, dd, J=7.4 Hz, 6.8Hz), 7.65 (1H, dd, J=7.8 Hz, 7.4 Hz), 7.40 (1H, d, J=6.8 Hz), 7.38 (1H, d, J=7.8 Hz), 7.34 (2H, d, J=7.4 Hz), 7.04 (2H, m), 5.03 (1H, m), 4.66 (1H, m), 4.06-3.16 (4H, m), 2.08-1.87 (2H, m), 1.73-1.45 (2H, m), 1.31 (3H, d, J=6.6 Hz). IR (KBr) cm-1: 2945, 1690, 1640, 1500, 1240. MS (ESI, m/z): 455 (M+H)+. HRMS (ESI, m/z): 455.1478 (Calcd for C23H24ClN4O4: 455.1486).

The synthetic route of 1204-75-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

1204-75-7, 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The resulting compound (228 mg, 0.682 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (133 mg, 0.682 mmol) to afford the desired title compound (174 mg, yield 52%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.84 (1H, brs), 9.54 (1H, brs), 7.90-7.83 (1H, m), 7.65 (1H, dd, J=8.6 Hz, 8.2 Hz), 7.40 (1H, d, J=7.4 Hz), 7.38 (1H, d, J=8.6 Hz), 7.35-7.27 (2H, m), 7.27-7.07 (1H, m), 4.99 (1H, m), 4.59 (1H, m), 4.02-3.78 (2H, m), 3.57-3.20 (2H, m), 2.09-1.49 (6H, m), 0.92 (3H, t, J=7.0 Hz). IR (KBr) cm-1: 2940, 1685, 1640, 1505, 1210. MS (ESI, m/z): 471 (M+H)+. HRMS (ESI, m/z): 471.1848 (Calcd for C24H25F2N4O4: 471.1844).

As the paragraph descriping shows that 1204-75-7 is playing an increasingly important role.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.

The resulting compound (124 mg, 0.350 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (68.6 mg, 0.350 mmol) to afford the desired title compound (74.2 mg, yield 47%) as a yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.85 (1H, brs), 9.58 (1H, d, J=7.0 Hz), 8.16 (1H, d, J=2.6 Hz), 7.88 (1H, dd, J=7.4 Hz, 5.4 Hz), 7.74-7.62 (2H, m), 7.40 (1H, d, J=7.4 Hz), 7.38 (1H, d, J=8.2 Hz), 6.93-6.84 (1H, m), 5.19 (1H, m), 5.00 (1H, m), 4.08-3.81 (2H, m), 3.58-3.16 (2H, m), 2.15-1.92 (2H, m), 1.88-1.48 (4H, m), 0.92 (3H, t, J=7.4 Hz). IR (KBr) cm-1: 2950, 1690, 1630, 1480, 1215. MS (ESI, m/z): 454 (M+H)+. HRMS (ESI, m/z): 454.1890 (Calcd for C23H25FN5O4: 454.1891).

The synthetic route of 1204-75-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

25983-13-5, 6,7-Dichloroquinoxaline-2,3(1H,4H)-dione is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

This product was used in the next reaction without further purification. 5-Nitro-6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione: 3.335 g (14.5 mmol) of 6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione was dissolved in 65 mL of conc. H2 SO4 with stirring and cooling in an ice-H2 O bath, then 2.20 g (21.76 mmol) of KNO3 (Baker, used as received) was added in portions over 10 min. with stirring. The resulting mixture was stirred at 22 C. under N2 for 20 h. then was slowly poured into ice-H2 O (400 mL) with stirring. The precipitate was collected on a sintered funnel by vacuum filtration, washed with H2 O (5*10 mL), and dried at 60 C. under 0.1 mmHg for 12 h affording 3.39 g (85%) of the crude 6,7-dichloro-5-nitro-1,4-dihydroquinoxaline-2,3-dione as a grey-yellow powder. Purity: >98.5% based on HPLC analysis.

25983-13-5 6,7-Dichloroquinoxaline-2,3(1H,4H)-dione 1845, aquinoxaline compound, is more and more widely used in various.

Reference£º
Patent; The State of Oregon, acting by and through The Oregon State Board of Higher Education, acting for and on behalf of The Oregon Health Sciences University; The University of Oregon; The Regents of the University of California; US5514680; (1996); A;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6924-66-9,Quinoxaline-5-carboxylic acid,as a common compound, the synthetic route is as follows.

PyBOP (206 mg, 396 muiotaetaomicronIota) was added to a mixture of 8-amino-2-(2-chloro-4-fluorophenyl)-2- azaspiro[4.5]decan-1 -one (isomer 1 ) (100 mg, 330 muiotaetaomicronIota, Intermediate 112), quinoxaline-5- carboxylic acid (71 .9 mg, 413 muiotaetaomicronIota) and N,N-diisopropylethylamine (290 muIota, 1 .7 mmol) in DMF (3.7 ml) and the mixture was stirred over night at room temperature. For work-up, the reaction mixture was concentrated and the residue was purified by preparative HPLC to give the title compound 65.0 mg (43 % yield).LC-MS (Method 1 ): Rt= 1 .14 min; MS (ESIpos): m/z = 453 [M+H]+ 1H-NMR (400 MHz, DMSO-d6): delta [ppm] = 9.78 (d, 1 H), 9.10-9.06 (m, 2H), 8.44 (dd, 1 H), 8.27 (dd, 1 H), 7.98 (dd, 1 H), 7.62-7.58 (m, 1 H), 7.49 (dd, 1 H), 7.35-7.28 (m, 1 H), 3.96-3.85 (m, 1 H), 3.66-3.60 (m, 2H), 2.16 (t, 2H), 2.09-2.00 (m, 2H), 1 .76-1 .66 (m, 4H), 1.60-1 .38 (m, 2H)

The synthetic route of 6924-66-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BAYER PHARMA AKTIENGESELLSCHAFT; BUCHGRABER, Philipp; EIS, Knut; WAGNER, Sarah; SUeLZLE, Detlev; VON NUSSBAUM, Franz; BENDER, Eckhard; LI, Volkhart, Min-Jian; LIU, Ningshu; SIEGEL, Franziska; LIENAU, Philipp; (248 pag.)WO2018/78005; (2018); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

53967-21-8, 6-(Bromomethyl)quinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of 6-(bromomethyl)quinoxaline (3 g, 13.5 mmol) and NaN3 (1.2 g, 18.5 mmol) in DMF (50 mL) was stirred at RT for 12h. The reaction was diluted with H2O (500 mL) and extracted with EtOAc (70 mL*3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated in vacuo to give 6-(azidomethyl)quinoxaline as a yellow solid which was used in the next step without further purification. (2.5 g crude). ESI-MS [M+H]+: 186.2.

53967-21-8 6-(Bromomethyl)quinoxaline 10214510, aquinoxaline compound, is more and more widely used in various.

Reference£º
Patent; Shire Human Genetic Therapies, Inc.; Papaioannou, Nikolaos; Fink, Sarah Jocelyn; Miller, Thomas Allen; Shipps, JR., Gerald Wayne; Travins, Jeremy Mark; Ehmann, David Edward; Rae, Alastair; Ellard, John Mark; (352 pag.)US2019/284182; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

34117-90-3, 3-Chloroquinoxalin-2-amine is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Heating a mixture of 2a (495 mg, 2.75 mmol) and Ph2PH (0.48 mL, 2.76 mmol) in the presence of Pd(OAc)2 (0.8 mg, 0.13 mol%) for 2 h at 130C led to a viscous blue-green mass. Extraction of the soluble part with diethyl ether and NMR monitoring in C6D6 identified Ph2P-PPh2, Ph2PCl, 3a and an unknown phosphorus compound (31P signals at d 14.9, 82.2, 12.8 and 5.4 ppm, intensity ratio 84:12:2:2). The insoluble hydrochloride part, 615 mg blue-green powder, was treated with aqueous NaOH/Et2O. The ether phase was dried with Na2SO4 and the ether removed in vacuo to give a brownish-yellow viscous mass (220 mg) with a low content of 3a (relative 31P intensity ca. 20% besides signals of Ph4P2, Ph2PHO and other P compounds). Purification under aerobic conditions by column chromatography on silica gel (ethyl acetate/hexane 95/5%) and removal of solvent gave 180 mg (45%) pale yellow solid 2-aminoquinoxaline. Mp: 156C. 1H NMR (CDCl3) d: 5.03 (vbr s, 2H, NH2), 7.45 (td, 3J = 8.4, 7, 4J = 1.2 Hz, 1H, H-6), 7.61 (td, 3J = 8.4, 7, 4J = 1.2 Hz, 1H, H-7), 7.67 (dd, 3J = 8.4, 4J = 1.2 Hz, 1H, H-8), 7.92 (dd, 3J = 8.4, 4J = 1.2 Hz, 1H, H-5), 8.35 (s, 1H, H-3); these values are in good agreement with the reported data [17]. 13C NMR (CDCl3) d: 125.05 (CH-6), 125.88 (CH-8), 128.83 (CH-5), 137.43 (Cq-4a), 137.78 (CH-3), 130.29 (CH-7), 140.89 (Cq-8a), 151.97 (Cq-2). HRMS (ESI in MeOH): Calc. for C8H7N3 [M+H+] 146.0713; found: 146.0713.

34117-90-3 3-Chloroquinoxalin-2-amine 817274, aquinoxaline compound, is more and more widely used in various.

Reference£º
Article; Adam, Mohamed Shaker S.; Mohamad, Ahmad Desoky; Jones, Peter G.; Kindermann, Markus K.; Heinicke, Joachim W.; Polyhedron; vol. 50; 1; (2013); p. 101 – 111;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.887590-25-2,tert-Butyl 3,4-dihydroquinoxaline-1(2H)-carboxylate,as a common compound, the synthetic route is as follows.

To a solution of N,N’-carbonyldiimidazole (363 mg) and triethylamine (312 mul) in chloroform (10 ml), E-4-aminoadamantan-1-ol obtained in Reference Example 2 (250 mg) and N,N-dimethylformamide (4 ml) were added and stirred at room temperature for 1 hour. To the reaction mixture, tert-butyl 3,4-dihydroquinoxaline-1(2H)-carboxylate obtained in Reference Example 28 (698 mg) was added and heated under reflux for 6 hours, followed by stirring overnight at room temperature. The reaction mixture was then heated under reflux for an additional 8 hours. After cooling at room temperature, the reaction mixture was diluted with water and extracted with chloroform. The organic layer was concentrated under reduced pressure, and the residue was diluted with ethyl acetate and washed sequentially with 0.1M aqueous hydrochloric acid, saturated aqueous sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate and then filtered to remove the desiccant, followed by distilling off the solvent under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluding solvent: n-hexane:ethyl acetate = 5:1 to 1:1 ? chloroform:methanol = 9:1) to give the titled compound (Compound 31, 290 mg) as a colorless amorphous substance. 1H NMR (300 MHz, CHLOROFORM-D) delta 1.35 (s, 1 H), 1.43-1.61 (m, 13 H), 1.70-1.79 (m, 4 H), 1.84-1.93 (m, 2 H), 2.06-2.19 (m, 3 H), 3.80-3.86 (m, 4 H), 3.89-3.97 (m, 1 H), 5.38 (d, J=6.5 Hz, 1 H), 7.04-7.20 (m, 2 H), 7.28-7.33 (m, 1 H), 8.00-8.05 (m, 1 H).

887590-25-2 tert-Butyl 3,4-dihydroquinoxaline-1(2H)-carboxylate 16740533, aquinoxaline compound, is more and more widely used in various.

Reference£º
Patent; Taisho Pharmaceutical Co. Ltd.; EP2172453; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider